{"success":true,"data":{"pressRelease":{"id":"135607","rtpr_id":"nGNX4wH7cz","ticker":"AGMB","exchange":"NASDAQ","all_tickers":["AGMB"],"title":"Agomab to Participate in Upcoming Investor Conferences","author":"Globe Newswire","published_at":"2026-09-03T20:05:00.558Z","article_body":"Antwerp, Belgium, September 3, 2026 – Agomab Therapeutics NV\n(https://www.globenewswire.com/Tracker?data=fre3DB4hUemTQt3bio6SpDdDTrNsXxlyuWIex1hGTEo6WuBunFdR8AfKk_YWzyKld8DKmWy27-i6Q3hKhemsyO8EfnIfqw50HYUGvStkJg4=)\n(Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company\nfocused on fibro-inflammation, today announced that members of the management\nteam will participate in the following upcoming investor conferences:\n* Citi's 2026 Biopharma Back to School Conference. Thursday, September 10,\n2026 in New York, NY.\n\n\n* 2026 Cantor Global Healthcare Conference. Fireside chat on Friday, September\n11, 2026 at 8:00 AM ET in New York, NY.\n\n\n* H.C. Wainwright 28th Annual Global Investment Conference. Fireside chat on\nTuesday, September 15, 2026 at 2:00 PM ET in New York, NY.\n\n\n* Morgan Stanley 24th Annual Global Healthcare Conference. Fireside chat on\nWednesday, September 16, 2026 at 9:15 AM ET in New York, NY.\nAbout Agomab\nAgomab is a clinical-stage biopharmaceutical company focused on developing\nnovel disease-modifying therapies for fibro-inflammatory diseases with high\nunmet medical need. Agomab’s product candidates are designed to target\nestablished, potent pathways and utilize organ-restricted approaches, with\nthe aim of increasing efficacy while minimizing safety liabilities. Fostering\na culture of excellence, Agomab’s mission is to pioneer therapeutics that\naim to resolve fibro-inflammation and restore organ function to enable people\nwith these disorders to live fuller and healthier lives.\n\nContacts\nInvestors\nSofie Van Gijsel\nVP of Investor Relations\nE-Mail: sofie.vangijsel@agomab.com\nPhone: +1 781 296 1143\n        \nMedia\nGretchen Schweitzer\nTrophic Communications\nE-Mail: agomab@trophic.eu \nPhone: +49 172 861 8540\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/7f797bcb-5d5d-4fb6-a862-b5c861b83e54)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX4wH7cz","title":"Agomab to Participate in Upcoming Investor Conferences","author":"Globe Newswire","ticker":"AGMB","created":"2026-09-03T20:05:00.558Z","tickers":["AGMB"],"exchange":"NASDAQ","article_body":"Antwerp, Belgium, September 3, 2026 – Agomab Therapeutics NV\n(https://www.globenewswire.com/Tracker?data=fre3DB4hUemTQt3bio6SpDdDTrNsXxlyuWIex1hGTEo6WuBunFdR8AfKk_YWzyKld8DKmWy27-i6Q3hKhemsyO8EfnIfqw50HYUGvStkJg4=)\n(Nasdaq: AGMB) (“Agomab”), a clinical-stage biopharmaceutical company\nfocused on fibro-inflammation, today announced that members of the management\nteam will participate in the following upcoming investor conferences:\n* Citi's 2026 Biopharma Back to School Conference. Thursday, September 10,\n2026 in New York, NY.\n\n\n* 2026 Cantor Global Healthcare Conference. Fireside chat on Friday, September\n11, 2026 at 8:00 AM ET in New York, NY.\n\n\n* H.C. Wainwright 28th Annual Global Investment Conference. Fireside chat on\nTuesday, September 15, 2026 at 2:00 PM ET in New York, NY.\n\n\n* Morgan Stanley 24th Annual Global Healthcare Conference. Fireside chat on\nWednesday, September 16, 2026 at 9:15 AM ET in New York, NY.\nAbout Agomab\nAgomab is a clinical-stage biopharmaceutical company focused on developing\nnovel disease-modifying therapies for fibro-inflammatory diseases with high\nunmet medical need. Agomab’s product candidates are designed to target\nestablished, potent pathways and utilize organ-restricted approaches, with\nthe aim of increasing efficacy while minimizing safety liabilities. Fostering\na culture of excellence, Agomab’s mission is to pioneer therapeutics that\naim to resolve fibro-inflammation and restore organ function to enable people\nwith these disorders to live fuller and healthier lives.\n\nContacts\nInvestors\nSofie Van Gijsel\nVP of Investor Relations\nE-Mail: sofie.vangijsel@agomab.com\nPhone: +1 781 296 1143\n        \nMedia\nGretchen Schweitzer\nTrophic Communications\nE-Mail: agomab@trophic.eu \nPhone: +49 172 861 8540\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/7f797bcb-5d5d-4fb6-a862-b5c861b83e54)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-03T20:05:00.607618438Z","server_sent_at_ms":1788465900607},"received_at":"2026-09-03T20:05:00.669Z","source_url":null},"analysis":{"id":"124479","press_release_id":"135607","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Agomab Therapeutics, a clinical-stage biopharmaceutical company focused on fibro-inflammation, announced management participation in four September investor conferences.\n\nFireside chats are scheduled at the Cantor Global Healthcare (Sept 11), H.C. Wainwright Global Investment (Sept 15), and Morgan Stanley Global Healthcare (Sept 16) conferences in New York, following Citi's Biopharma Back to School Conference on Sept 10.\n\nThe release contains no new clinical, financial, or pipeline information and is a routine investor-outreach calendar notice.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference-calendar notice with no new data -- suppress unless conference commentary later becomes newsworthy."},"keyFigures":{},"quotedText":"","namedEntities":{"people":[{"name":"Sofie Van Gijsel","role":"VP of Investor Relations"},{"name":"Gretchen Schweitzer","role":"media contact, Trophic Communications"}],"products":[],"companies":[{"name":"Agomab Therapeutics NV","ticker":"AGMB","relationship":"filer"},{"name":"Citi","relationship":"conference host"},{"name":"Cantor Fitzgerald","relationship":"conference host"},{"name":"H.C. Wainwright","relationship":"conference host"},{"name":"Morgan Stanley","relationship":"conference host"},{"name":"Trophic Communications","relationship":"media relations agency"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine investor-conference calendar announcement with no new clinical, financial, or strategic disclosures. Purely administrative scheduling news from the issuer."},"tickerRelevance":{"others":[],"primary":"AGMB"},"globalImportance":5,"audienceRelevance":8,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"conference-participation-notice","sectorWeight":"biotech","issuerAuthored":true,"newInformation":false}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Agomab Therapeutics, a clinical-stage biopharmaceutical company focused on fibro-inflammation, announced management participation in four September investor conferences.\n\nFireside chats are scheduled at the Cantor Global Healthcare (Sept 11), H.C. Wainwright Global Investment (Sept 15), and Morgan Stanley Global Healthcare (Sept 16) conferences in New York, following Citi's Biopharma Back to School Conference on Sept 10.\n\nThe release contains no new clinical, financial, or pipeline information and is a routine investor-outreach calendar notice.","key_figures":{},"named_entities":{"people":[{"name":"Sofie Van Gijsel","role":"VP of Investor Relations"},{"name":"Gretchen Schweitzer","role":"media contact, Trophic Communications"}],"products":[],"companies":[{"name":"Agomab Therapeutics NV","ticker":"AGMB","relationship":"filer"},{"name":"Citi","relationship":"conference host"},{"name":"Cantor Fitzgerald","relationship":"conference host"},{"name":"H.C. Wainwright","relationship":"conference host"},{"name":"Morgan Stanley","relationship":"conference host"},{"name":"Trophic Communications","relationship":"media relations agency"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-03T20:09:16.117Z","global_importance":5,"audience_relevance":8,"importance_components":{"tickerTier":"small-cap","eventGravity":"conference-participation-notice","sectorWeight":"biotech","issuerAuthored":true,"newInformation":false}},"durationMs":24674,"modelName":"glm-4.7"}}